Back to Authors

Gertz, Morie A

0000-0002-3853-5196

Mayo Clinic

Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.

Citations 172

Multiple myeloma – a cure within reach
Gertz, Morie A. , Gertz, Morie A

Leukemia & Lymphoma | April 4, 2018 | Volume: 59 | Issue: 11 | Pages: 2521-2523

10.1080/10428194.2018.1452221 Get It

Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation
Sidiqi, M Hasib , Aljama, Mohammed A. , Muchtar, Eli , Warsame, Rahma , Lacy, Martha Q. , Dingli, David , Kumar, Shaji , Kapoor, Prashant , Kourelis, Taxiarchis , Buadi, Francis K. , Kourelis, Taxiarchis V, Gertz, Morie A , Muchtar, E , Sidiqi, M Hasib , Dingli, David , Dispenzieri, Angela , Leung, Nelson , Gonsalves, Wilson I. , Hogan, William J. , Gertz, Morie A.

Blood Advances | April 3, 2018 | Volume: 2 | Issue: 7 | Pages: 769-776

10.1182/bloodadvances.2018016782 Get It

Key Points λ Light chain AL amyloidosis is associated with a shorter PFS and OS compared with κ. Light chain type predicts likelihood of organ involvement in AL amyloidosis.
Testicular plasmacytoma: unique location or circumstantial presentation?
Muchtar, Eli , Bladé, Joan , Gertz, Morie A. , Gertz, Morie A , Muchtar, E

Leukemia & Lymphoma | January 10, 2018 | Volume: 59 | Issue: 8 | Pages: 1769-1771

10.1080/10428194.2017.1421763 Get It

Attitudes about when and how to treat patients with AL amyloidosis: an international survey
Milani, Paolo , Gertz, Morie A. , Merlini, Giampaolo , Dispenzieri, Angela , Gertz, Morie A , Merlini, Giampaolo , Milani, Paolo , Dispenzieri, Angela

Amyloid | August 31, 2017 | Volume: 24 | Issue: 4 | Pages: 213-216

10.1080/13506129.2017.1370421 Get It

Delineation of the timing of second-line therapy post–autologous stem cell transplant in patients with AL amyloidosis
Hwa, Yi L. , Warsame, Rahma , Gertz, Morie A. , Buadi, Francis K. , Lacy, Martha Q. , Kumar, Shaji , Dingli, David , Zeldenrust, Steve R., Hayman, Susanne R., Kapoor, Prashant , Kourelis, Taxiarchis , Russell, Stephen J. , Hobbs, Miriam, Fonder, Amie , Dispenzieri, Angela , Gertz, Morie A , Buadi, Francis K , Russell, Stephen J , Dingli, David , Zeldenrust, Steven R., Leung, Nelson , Gonsalves, Wilson I. , Go, Ronald S. , Rajkumar, S. Vincent , Dispenzieri, Angela

Blood | August 14, 2017 | Volume: 130 | Issue: 13 | Pages: 1578-1584

10.1182/blood-2017-05-783415 Get It

Key Points Organ progression at second-line therapy predicated inferior survival. Patients relapsing from >VGPR had a longer time to develop organ progression.
Elevation of serum lactate dehydrogenase in AL amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation
Muchtar, Eli , Lacy, Martha Q. , Kapoor, Prashant , Hayman, Suzanne R. , Gonsalves, Wilson I. , Warsame, Rahma , Kourelis, Taxiarchis , Chakraborty, Rajshekhar , Russell, Stephen J. , Lust, John A., Lin, Yi , Zeldenrust, Steven R., Dingli, David , Kyle, Robert A. , Kumar, Shaji , Buadi, Francis K. , Gonsalves, Wilson , Kourelis, Taxiarchis V, Russell, Stephen, Zeldenrust, Steven, Kumar, Shaji K , Gertz, Morie A , Dispenzieri, Angela , Go, Ronald S. , Leung, Nelson , Rajkumar, S. Vincent , Gertz, Morie A. , Muchtar, E , Russell, Stephen J , Chakraborty, Rajshekhar , Dingli, David , Lin, Yi

British Journal of Haematology | July 12, 2017 | Volume: 178 | Issue: 6 | Pages: 888-895

10.1111/bjh.14830 Get It

SummaryThe significance of serum lactate dehydrogenase (LDH) in light chain (AL) amyloidosis has not been previously explored. We studied 1019 newly diagnosed patients and correlated the elevation of LDH above the upper limit of normal (ULN) with disease characteristics and outcome. Four hundred and nine patients had an LDH above ULN, representing 40% of the study population. Patients with an elevated LDH were older, were less likely to be male and had more extensive organ involvement compared to patients with a normal LDH. Patients with high LDH had greater cardiac and renal dysfunction. Elevated LDH was an independent prognostic marker for overall survival and for death within 6 months of diagnosis, but this was restricted to patients not eligible for stem cell transplant. Serum LDH may act as a marker for organ damage and should be explored as a potential marker for tissue healing and organ recovery.
Diagnosis and management of smoldering multiple myeloma: the razor’s edge between clonality and cancer
Muchtar, Eli , Kumar, Shaji , Magen, Hila , Gertz, Morie A. , Kumar, Shaji K , Gertz, Morie A , Muchtar, E

Leukemia & Lymphoma | June 8, 2017 | Volume: 59 | Issue: 2 | Pages: 288-299

10.1080/10428194.2017.1334124 Get It

Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death
Muchtar, Eli , Gertz, Morie A. , Kumar, Shaji , Lacy, Martha Q. , Dingli, David , Grogan, Martha , Hayman, Suzanne R. , Kapoor, Prashant , Fonder, Amie , Hobbs, Miriam, Hwa, Yi L. , Warsame, Rahma , Kourelis, Taxiarchis , Russell, Stephen J. , Lust, John A., Lin, Yi , Zeldenrust, Steven R., Kyle, Robert A. , Buadi, Francis K. , Leung, Nelson , Gonsalves, Wilson I. , Go, Ronald S. , Rajkumar, S. Vincent , Dispenzieri, Angela , Gertz, Morie A , Muchtar, E , Russell, Stephen J , Dingli, David , Lin, Yi

Blood | January 26, 2017 | Volume: 129 | Issue: 15 | Pages: 2111-2119

10.1182/blood-2016-11-751628 Get It

Key Points Significant improvement in outcome is a reality for newly diagnosed AL amyloidosis in the past decade. Six-month mortality among transplant ineligible patients has declined since 2005.
How I treat cryoglobulinemia
Muchtar, Eli , Magen, Hila , Gertz, Morie A. , Gertz, Morie A , Muchtar, E

Blood | October 31, 2016 | Volume: 129 | Issue: 3 | Pages: 289-298

10.1182/blood-2016-09-719773 Get It

Abstract Cryoglobulinemia is a distinct entity characterized by the presence of cryoglobulins in the serum. Cryoglobulins differ in their composition, which has an impact on the clinical presentation and the underlying disease that triggers cryoglobulin formation. Cryoglobulinemia is categorized into two main subgroups: type I, which is seen exclusively in clonal hematologic diseases, and type II/III, which is called mixed cryoglobulinemia and is seen in hepatitis C virus infection and systemic diseases such as B-cell lineage hematologic malignancies and connective tissue disorders. Clinical presentation is broad and varies between types but includes arthralgia, purpura, skin ulcers, glomerulonephritis, and peripheral neuropathy. Life-threatening manifestations can develop in a small proportion of patients. A full evaluation for the underlying cause is required, because each type requires a different kind of treatment, which should be tailored on the basis of disease severity, underlying disease, and prior therapies. Relapses can be frequent and can result in significant morbidity and cumulative organ impairment. We explore the spectrum of this heterogeneous disease by discussing the disease characteristics of 5 different patients.